nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—pancreatic cancer—colon cancer	0.501	1	CtDrD
Sunitinib—ABCB1—colon cancer	0.0425	1	CbGaD
Sunitinib—ABCC4—Fluorouracil—colon cancer	0.0189	0.129	CbGbCtD
Sunitinib—ABCC2—Irinotecan—colon cancer	0.0117	0.0798	CbGbCtD
Sunitinib—ABCG2—Irinotecan—colon cancer	0.0106	0.0721	CbGbCtD
Sunitinib—ABCC4—Methotrexate—colon cancer	0.0104	0.071	CbGbCtD
Sunitinib—ABCC2—Vincristine—colon cancer	0.0103	0.0697	CbGbCtD
Sunitinib—ABCG2—Fluorouracil—colon cancer	0.0102	0.0692	CbGbCtD
Sunitinib—ABCG2—Vincristine—colon cancer	0.00927	0.063	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Irinotecan—colon cancer	0.00783	0.0533	CbGbCtD
Sunitinib—CYP3A7—Irinotecan—colon cancer	0.00783	0.0533	CbGbCtD
Sunitinib—CYP3A7—Vincristine—colon cancer	0.00684	0.0466	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Vincristine—colon cancer	0.00684	0.0466	CbGbCtD
Sunitinib—ABCC2—Methotrexate—colon cancer	0.00621	0.0422	CbGbCtD
Sunitinib—CYP3A5—Irinotecan—colon cancer	0.00587	0.0399	CbGbCtD
Sunitinib—ABCG2—Methotrexate—colon cancer	0.00561	0.0382	CbGbCtD
Sunitinib—CYP3A5—Vincristine—colon cancer	0.00513	0.0349	CbGbCtD
Sunitinib—ABCB1—Irinotecan—colon cancer	0.00382	0.026	CbGbCtD
Sunitinib—ABCB1—Vincristine—colon cancer	0.00334	0.0227	CbGbCtD
Sunitinib—CYP3A4—Irinotecan—colon cancer	0.00229	0.0156	CbGbCtD
Sunitinib—ABCB1—Methotrexate—colon cancer	0.00202	0.0138	CbGbCtD
Sunitinib—CYP3A4—Vincristine—colon cancer	0.002	0.0136	CbGbCtD
Sunitinib—DYRK1A—Topotecan—Irinotecan—colon cancer	0.000828	0.389	CbGdCrCtD
Sunitinib—PLK4—Topotecan—Irinotecan—colon cancer	0.000565	0.266	CbGdCrCtD
Sunitinib—CHEK2—Vindesine—Vincristine—colon cancer	0.000356	0.167	CbGdCrCtD
Sunitinib—CHEK2—Vinorelbine—Vincristine—colon cancer	0.000225	0.106	CbGdCrCtD
Sunitinib—CHEK2—Vinblastine—Vincristine—colon cancer	0.000155	0.0726	CbGdCrCtD
Sunitinib—IRAK4—bone marrow—colon cancer	0.000117	0.00128	CbGeAlD
Sunitinib—TAOK3—renal system—colon cancer	0.000117	0.00128	CbGeAlD
Sunitinib—RET—lymphoid tissue—colon cancer	0.000117	0.00128	CbGeAlD
Sunitinib—FGR—lymphoid tissue—colon cancer	0.000117	0.00128	CbGeAlD
Sunitinib—AXL—lymphoid tissue—colon cancer	0.000116	0.00128	CbGeAlD
Sunitinib—ROCK1—liver—colon cancer	0.000116	0.00128	CbGeAlD
Sunitinib—CHEK2—lymph node—colon cancer	0.000116	0.00127	CbGeAlD
Sunitinib—NUAK1—lymph node—colon cancer	0.000116	0.00127	CbGeAlD
Sunitinib—PDGFRA—renal system—colon cancer	0.000116	0.00127	CbGeAlD
Sunitinib—RPS6KB1—digestive system—colon cancer	0.000116	0.00127	CbGeAlD
Sunitinib—PTK2B—vagina—colon cancer	0.000116	0.00127	CbGeAlD
Sunitinib—FGR—digestive system—colon cancer	0.000115	0.00127	CbGeAlD
Sunitinib—RET—digestive system—colon cancer	0.000115	0.00127	CbGeAlD
Sunitinib—OXSR1—lymph node—colon cancer	0.000115	0.00126	CbGeAlD
Sunitinib—SNRK—lymph node—colon cancer	0.000115	0.00126	CbGeAlD
Sunitinib—INSR—lymph node—colon cancer	0.000115	0.00126	CbGeAlD
Sunitinib—MAP2K2—bone marrow—colon cancer	0.000114	0.00125	CbGeAlD
Sunitinib—ULK3—bone marrow—colon cancer	0.000114	0.00125	CbGeAlD
Sunitinib—CSNK1E—vagina—colon cancer	0.000114	0.00125	CbGeAlD
Sunitinib—FGFR1—vagina—colon cancer	0.000114	0.00125	CbGeAlD
Sunitinib—MAP3K2—bone marrow—colon cancer	0.000113	0.00125	CbGeAlD
Sunitinib—DYRK1A—liver—colon cancer	0.000113	0.00124	CbGeAlD
Sunitinib—RPS6KA2—lymph node—colon cancer	0.000113	0.00124	CbGeAlD
Sunitinib—STK38—lymph node—colon cancer	0.000113	0.00124	CbGeAlD
Sunitinib—KDR—epithelium—colon cancer	0.000113	0.00124	CbGeAlD
Sunitinib—MAP3K7—bone marrow—colon cancer	0.000112	0.00123	CbGeAlD
Sunitinib—AURKC—lymph node—colon cancer	0.000112	0.00123	CbGeAlD
Sunitinib—IRAK4—vagina—colon cancer	0.000112	0.00123	CbGeAlD
Sunitinib—PKN1—lymph node—colon cancer	0.000111	0.00122	CbGeAlD
Sunitinib—CSNK1G2—lymph node—colon cancer	0.000111	0.00122	CbGeAlD
Sunitinib—TBK1—bone marrow—colon cancer	0.000111	0.00122	CbGeAlD
Sunitinib—MERTK—liver—colon cancer	0.000111	0.00121	CbGeAlD
Sunitinib—TYK2—bone marrow—colon cancer	0.00011	0.00121	CbGeAlD
Sunitinib—JAK2—lymphoid tissue—colon cancer	0.00011	0.00121	CbGeAlD
Sunitinib—PRPF4—lymph node—colon cancer	0.00011	0.00121	CbGeAlD
Sunitinib—FGFR2—digestive system—colon cancer	0.000109	0.0012	CbGeAlD
Sunitinib—ULK3—vagina—colon cancer	0.000109	0.0012	CbGeAlD
Sunitinib—IRAK1—bone marrow—colon cancer	0.000109	0.0012	CbGeAlD
Sunitinib—JAK2—digestive system—colon cancer	0.000109	0.0012	CbGeAlD
Sunitinib—FYN—lymphoid tissue—colon cancer	0.000109	0.00119	CbGeAlD
Sunitinib—KDR—smooth muscle tissue—colon cancer	0.000109	0.00119	CbGeAlD
Sunitinib—MAP4K4—liver—colon cancer	0.000109	0.00119	CbGeAlD
Sunitinib—PRPF4B—lymph node—colon cancer	0.000108	0.00119	CbGeAlD
Sunitinib—NUAK2—liver—colon cancer	0.000108	0.00118	CbGeAlD
Sunitinib—MAP3K7—vagina—colon cancer	0.000108	0.00118	CbGeAlD
Sunitinib—FYN—digestive system—colon cancer	0.000107	0.00118	CbGeAlD
Sunitinib—MAP3K12—liver—colon cancer	0.000107	0.00118	CbGeAlD
Sunitinib—FLT3—liver—colon cancer	0.000107	0.00118	CbGeAlD
Sunitinib—RPS6KB1—bone marrow—colon cancer	0.000107	0.00117	CbGeAlD
Sunitinib—STK39—lymph node—colon cancer	0.000107	0.00117	CbGeAlD
Sunitinib—TBK1—vagina—colon cancer	0.000106	0.00117	CbGeAlD
Sunitinib—MAP4K5—lymphoid tissue—colon cancer	0.000106	0.00117	CbGeAlD
Sunitinib—FGR—bone marrow—colon cancer	0.000106	0.00117	CbGeAlD
Sunitinib—CSF1R—smooth muscle tissue—colon cancer	0.000106	0.00116	CbGeAlD
Sunitinib—TYK2—vagina—colon cancer	0.000106	0.00116	CbGeAlD
Sunitinib—RPS6KA3—liver—colon cancer	0.000106	0.00116	CbGeAlD
Sunitinib—CSNK2A1—lymph node—colon cancer	0.000105	0.00116	CbGeAlD
Sunitinib—MAP2K1—liver—colon cancer	0.000105	0.00115	CbGeAlD
Sunitinib—KDR—renal system—colon cancer	0.000105	0.00115	CbGeAlD
Sunitinib—MYLK—lymph node—colon cancer	0.000104	0.00114	CbGeAlD
Sunitinib—CSNK1A1—liver—colon cancer	0.000103	0.00114	CbGeAlD
Sunitinib—CLK1—liver—colon cancer	0.000103	0.00113	CbGeAlD
Sunitinib—PLK4—lymph node—colon cancer	0.000103	0.00113	CbGeAlD
Sunitinib—FLT1—lymphoid tissue—colon cancer	0.000103	0.00113	CbGeAlD
Sunitinib—RPS6KB1—vagina—colon cancer	0.000102	0.00112	CbGeAlD
Sunitinib—STK4—lymph node—colon cancer	0.000102	0.00112	CbGeAlD
Sunitinib—SLK—bone marrow—colon cancer	0.000102	0.00112	CbGeAlD
Sunitinib—FGR—vagina—colon cancer	0.000102	0.00112	CbGeAlD
Sunitinib—FLT1—digestive system—colon cancer	0.000101	0.00111	CbGeAlD
Sunitinib—AXL—vagina—colon cancer	0.000101	0.00111	CbGeAlD
Sunitinib—CAMK2G—liver—colon cancer	0.000101	0.00111	CbGeAlD
Sunitinib—BMP2K—liver—colon cancer	0.000101	0.00111	CbGeAlD
Sunitinib—JAK2—bone marrow—colon cancer	0.0001	0.0011	CbGeAlD
Sunitinib—PHKG2—lymph node—colon cancer	0.0001	0.0011	CbGeAlD
Sunitinib—LRRK2—liver—colon cancer	0.0001	0.0011	CbGeAlD
Sunitinib—KIT—epithelium—colon cancer	9.99e-05	0.0011	CbGeAlD
Sunitinib—STK24—lymph node—colon cancer	9.97e-05	0.0011	CbGeAlD
Sunitinib—FYN—bone marrow—colon cancer	9.9e-05	0.00109	CbGeAlD
Sunitinib—DAPK2—lymph node—colon cancer	9.86e-05	0.00108	CbGeAlD
Sunitinib—PRKAA1—liver—colon cancer	9.86e-05	0.00108	CbGeAlD
Sunitinib—Back pain—Irinotecan—colon cancer	9.84e-05	0.00111	CcSEcCtD
Sunitinib—Abdominal distension—Capecitabine—colon cancer	9.84e-05	0.00111	CcSEcCtD
Sunitinib—YES1—lymphoid tissue—colon cancer	9.81e-05	0.00108	CbGeAlD
Sunitinib—Muscle spasms—Irinotecan—colon cancer	9.78e-05	0.00111	CcSEcCtD
Sunitinib—Dysphagia—Capecitabine—colon cancer	9.77e-05	0.00111	CcSEcCtD
Sunitinib—PDGFRB—epithelium—colon cancer	9.76e-05	0.00107	CbGeAlD
Sunitinib—SLK—vagina—colon cancer	9.75e-05	0.00107	CbGeAlD
Sunitinib—PTK2B—liver—colon cancer	9.75e-05	0.00107	CbGeAlD
Sunitinib—Erythema—Fluorouracil—colon cancer	9.74e-05	0.0011	CcSEcCtD
Sunitinib—STK10—lymphoid tissue—colon cancer	9.72e-05	0.00107	CbGeAlD
Sunitinib—FLT4—liver—colon cancer	9.72e-05	0.00107	CbGeAlD
Sunitinib—STK16—lymph node—colon cancer	9.7e-05	0.00107	CbGeAlD
Sunitinib—YES1—digestive system—colon cancer	9.69e-05	0.00106	CbGeAlD
Sunitinib—TAOK3—lymphoid tissue—colon cancer	9.68e-05	0.00106	CbGeAlD
Sunitinib—MAP4K5—bone marrow—colon cancer	9.67e-05	0.00106	CbGeAlD
Sunitinib—MAP3K3—bone marrow—colon cancer	9.67e-05	0.00106	CbGeAlD
Sunitinib—Anaemia—Vincristine—colon cancer	9.65e-05	0.00109	CcSEcCtD
Sunitinib—HIPK2—lymph node—colon cancer	9.65e-05	0.00106	CbGeAlD
Sunitinib—HIPK3—lymph node—colon cancer	9.65e-05	0.00106	CbGeAlD
Sunitinib—ALK—lymph node—colon cancer	9.65e-05	0.00106	CbGeAlD
Sunitinib—KIT—smooth muscle tissue—colon cancer	9.62e-05	0.00106	CbGeAlD
Sunitinib—PDGFRA—lymphoid tissue—colon cancer	9.62e-05	0.00106	CbGeAlD
Sunitinib—JAK2—vagina—colon cancer	9.61e-05	0.00106	CbGeAlD
Sunitinib—STK10—digestive system—colon cancer	9.6e-05	0.00105	CbGeAlD
Sunitinib—CSNK1E—liver—colon cancer	9.59e-05	0.00105	CbGeAlD
Sunitinib—FGFR1—liver—colon cancer	9.59e-05	0.00105	CbGeAlD
Sunitinib—TAOK3—digestive system—colon cancer	9.57e-05	0.00105	CbGeAlD
Sunitinib—TNK1—lymph node—colon cancer	9.55e-05	0.00105	CbGeAlD
Sunitinib—RIOK2—lymph node—colon cancer	9.55e-05	0.00105	CbGeAlD
Sunitinib—PDGFRA—digestive system—colon cancer	9.51e-05	0.00104	CbGeAlD
Sunitinib—FYN—vagina—colon cancer	9.48e-05	0.00104	CbGeAlD
Sunitinib—MAP4K1—lymph node—colon cancer	9.45e-05	0.00104	CbGeAlD
Sunitinib—IRAK4—liver—colon cancer	9.44e-05	0.00104	CbGeAlD
Sunitinib—Anaemia—Irinotecan—colon cancer	9.4e-05	0.00107	CcSEcCtD
Sunitinib—PDGFRB—smooth muscle tissue—colon cancer	9.4e-05	0.00103	CbGeAlD
Sunitinib—Bronchitis—Capecitabine—colon cancer	9.4e-05	0.00106	CcSEcCtD
Sunitinib—Abdominal discomfort—Capecitabine—colon cancer	9.37e-05	0.00106	CcSEcCtD
Sunitinib—Hepatic failure—Methotrexate—colon cancer	9.37e-05	0.00106	CcSEcCtD
Sunitinib—Leukopenia—Vincristine—colon cancer	9.35e-05	0.00106	CcSEcCtD
Sunitinib—Pancytopenia—Capecitabine—colon cancer	9.28e-05	0.00105	CcSEcCtD
Sunitinib—DAPK3—lymph node—colon cancer	9.27e-05	0.00102	CbGeAlD
Sunitinib—MAP3K3—vagina—colon cancer	9.27e-05	0.00102	CbGeAlD
Sunitinib—MAP4K5—vagina—colon cancer	9.27e-05	0.00102	CbGeAlD
Sunitinib—KIT—renal system—colon cancer	9.26e-05	0.00102	CbGeAlD
Sunitinib—ULK3—liver—colon cancer	9.23e-05	0.00101	CbGeAlD
Sunitinib—MAP2K2—liver—colon cancer	9.23e-05	0.00101	CbGeAlD
Sunitinib—CLK2—lymph node—colon cancer	9.18e-05	0.00101	CbGeAlD
Sunitinib—MAP3K2—liver—colon cancer	9.16e-05	0.00101	CbGeAlD
Sunitinib—MAP4K2—lymph node—colon cancer	9.14e-05	0.001	CbGeAlD
Sunitinib—Neutropenia—Capecitabine—colon cancer	9.14e-05	0.00104	CcSEcCtD
Sunitinib—Renal failure acute—Methotrexate—colon cancer	9.12e-05	0.00103	CcSEcCtD
Sunitinib—Leukopenia—Irinotecan—colon cancer	9.11e-05	0.00103	CcSEcCtD
Sunitinib—Upper respiratory tract infection—Capecitabine—colon cancer	9.08e-05	0.00103	CcSEcCtD
Sunitinib—MAP3K7—liver—colon cancer	9.08e-05	0.000997	CbGeAlD
Sunitinib—Convulsion—Vincristine—colon cancer	9.05e-05	0.00103	CcSEcCtD
Sunitinib—PDGFRB—renal system—colon cancer	9.05e-05	0.000994	CbGeAlD
Sunitinib—Hypertension—Vincristine—colon cancer	9.02e-05	0.00102	CcSEcCtD
Sunitinib—STK3—lymph node—colon cancer	9.02e-05	0.000991	CbGeAlD
Sunitinib—Anaemia—Fluorouracil—colon cancer	9.01e-05	0.00102	CcSEcCtD
Sunitinib—TBK1—liver—colon cancer	8.97e-05	0.000986	CbGeAlD
Sunitinib—FLT1—vagina—colon cancer	8.96e-05	0.000984	CbGeAlD
Sunitinib—YES1—bone marrow—colon cancer	8.93e-05	0.000981	CbGeAlD
Sunitinib—TYK2—liver—colon cancer	8.91e-05	0.000979	CbGeAlD
Sunitinib—Myalgia—Vincristine—colon cancer	8.89e-05	0.00101	CcSEcCtD
Sunitinib—Cough—Irinotecan—colon cancer	8.88e-05	0.00101	CcSEcCtD
Sunitinib—EPHB6—vagina—colon cancer	8.85e-05	0.000973	CbGeAlD
Sunitinib—STK10—bone marrow—colon cancer	8.85e-05	0.000972	CbGeAlD
Sunitinib—Weight decreased—Capecitabine—colon cancer	8.84e-05	0.001	CcSEcCtD
Sunitinib—TAOK3—bone marrow—colon cancer	8.82e-05	0.000969	CbGeAlD
Sunitinib—Hyperglycaemia—Capecitabine—colon cancer	8.81e-05	0.000998	CcSEcCtD
Sunitinib—IRAK1—liver—colon cancer	8.8e-05	0.000966	CbGeAlD
Sunitinib—Hypertension—Irinotecan—colon cancer	8.78e-05	0.000995	CcSEcCtD
Sunitinib—Pneumonia—Capecitabine—colon cancer	8.76e-05	0.000993	CcSEcCtD
Sunitinib—Leukopenia—Fluorouracil—colon cancer	8.72e-05	0.000988	CcSEcCtD
Sunitinib—Infestation—Capecitabine—colon cancer	8.71e-05	0.000987	CcSEcCtD
Sunitinib—Infestation NOS—Capecitabine—colon cancer	8.71e-05	0.000987	CcSEcCtD
Sunitinib—Depression—Capecitabine—colon cancer	8.69e-05	0.000984	CcSEcCtD
Sunitinib—KDR—lymphoid tissue—colon cancer	8.68e-05	0.000954	CbGeAlD
Sunitinib—DYRK1A—lymph node—colon cancer	8.68e-05	0.000954	CbGeAlD
Sunitinib—Stevens-Johnson syndrome—Capecitabine—colon cancer	8.64e-05	0.000978	CcSEcCtD
Sunitinib—RPS6KB1—liver—colon cancer	8.63e-05	0.000948	CbGeAlD
Sunitinib—Acute coronary syndrome—Capecitabine—colon cancer	8.59e-05	0.000973	CcSEcCtD
Sunitinib—Cerebrovascular accident—Methotrexate—colon cancer	8.59e-05	0.000973	CcSEcCtD
Sunitinib—FGR—liver—colon cancer	8.58e-05	0.000943	CbGeAlD
Sunitinib—KDR—digestive system—colon cancer	8.57e-05	0.000942	CbGeAlD
Sunitinib—Renal failure—Capecitabine—colon cancer	8.56e-05	0.00097	CcSEcCtD
Sunitinib—YES1—vagina—colon cancer	8.56e-05	0.00094	CbGeAlD
Sunitinib—AXL—liver—colon cancer	8.55e-05	0.000939	CbGeAlD
Sunitinib—Neuropathy peripheral—Capecitabine—colon cancer	8.54e-05	0.000967	CcSEcCtD
Sunitinib—Oedema—Vincristine—colon cancer	8.53e-05	0.000966	CcSEcCtD
Sunitinib—Stomatitis—Capecitabine—colon cancer	8.49e-05	0.000962	CcSEcCtD
Sunitinib—STK10—vagina—colon cancer	8.48e-05	0.000931	CbGeAlD
Sunitinib—MERTK—lymph node—colon cancer	8.48e-05	0.000931	CbGeAlD
Sunitinib—CSF1R—lymphoid tissue—colon cancer	8.47e-05	0.000931	CbGeAlD
Sunitinib—Infection—Vincristine—colon cancer	8.47e-05	0.000959	CcSEcCtD
Sunitinib—Urinary tract infection—Capecitabine—colon cancer	8.47e-05	0.000959	CcSEcCtD
Sunitinib—TAOK3—vagina—colon cancer	8.45e-05	0.000928	CbGeAlD
Sunitinib—Convulsion—Fluorouracil—colon cancer	8.44e-05	0.000956	CcSEcCtD
Sunitinib—PDGFRA—vagina—colon cancer	8.39e-05	0.000922	CbGeAlD
Sunitinib—CSF1R—digestive system—colon cancer	8.37e-05	0.000919	CbGeAlD
Sunitinib—Nervous system disorder—Vincristine—colon cancer	8.36e-05	0.000947	CcSEcCtD
Sunitinib—Thrombocytopenia—Vincristine—colon cancer	8.35e-05	0.000946	CcSEcCtD
Sunitinib—MAP4K4—lymph node—colon cancer	8.32e-05	0.000914	CbGeAlD
Sunitinib—Oedema—Irinotecan—colon cancer	8.3e-05	0.00094	CcSEcCtD
Sunitinib—Chest pain—Fluorouracil—colon cancer	8.29e-05	0.00094	CcSEcCtD
Sunitinib—Myalgia—Fluorouracil—colon cancer	8.29e-05	0.00094	CcSEcCtD
Sunitinib—NUAK2—lymph node—colon cancer	8.26e-05	0.000908	CbGeAlD
Sunitinib—Infection—Irinotecan—colon cancer	8.25e-05	0.000934	CcSEcCtD
Sunitinib—Hepatobiliary disease—Capecitabine—colon cancer	8.24e-05	0.000933	CcSEcCtD
Sunitinib—SLK—liver—colon cancer	8.23e-05	0.000904	CbGeAlD
Sunitinib—Epistaxis—Capecitabine—colon cancer	8.22e-05	0.000931	CcSEcCtD
Sunitinib—FLT3—lymph node—colon cancer	8.2e-05	0.000901	CbGeAlD
Sunitinib—MAP3K12—lymph node—colon cancer	8.2e-05	0.000901	CbGeAlD
Sunitinib—CYP3A7—liver—colon cancer	8.2e-05	0.0009	CbGeAlD
Sunitinib—Shock—Irinotecan—colon cancer	8.17e-05	0.000925	CcSEcCtD
Sunitinib—FGFR2—liver—colon cancer	8.15e-05	0.000896	CbGeAlD
Sunitinib—Nervous system disorder—Irinotecan—colon cancer	8.14e-05	0.000922	CcSEcCtD
Sunitinib—Thrombocytopenia—Irinotecan—colon cancer	8.13e-05	0.000921	CcSEcCtD
Sunitinib—Anorexia—Vincristine—colon cancer	8.13e-05	0.000921	CcSEcCtD
Sunitinib—JAK2—liver—colon cancer	8.11e-05	0.000891	CbGeAlD
Sunitinib—RPS6KA3—lymph node—colon cancer	8.09e-05	0.000889	CbGeAlD
Sunitinib—MAP2K1—lymph node—colon cancer	8.04e-05	0.000883	CbGeAlD
Sunitinib—FYN—liver—colon cancer	8e-05	0.000879	CbGeAlD
Sunitinib—Bradycardia—Capecitabine—colon cancer	7.96e-05	0.000902	CcSEcCtD
Sunitinib—Oedema—Fluorouracil—colon cancer	7.95e-05	0.000901	CcSEcCtD
Sunitinib—CSNK1A1—lymph node—colon cancer	7.93e-05	0.000871	CbGeAlD
Sunitinib—Anorexia—Irinotecan—colon cancer	7.91e-05	0.000896	CcSEcCtD
Sunitinib—KDR—bone marrow—colon cancer	7.9e-05	0.000868	CbGeAlD
Sunitinib—Infection—Fluorouracil—colon cancer	7.9e-05	0.000895	CcSEcCtD
Sunitinib—CLK1—lymph node—colon cancer	7.88e-05	0.000866	CbGeAlD
Sunitinib—Haemoglobin—Capecitabine—colon cancer	7.86e-05	0.00089	CcSEcCtD
Sunitinib—Haemorrhage—Capecitabine—colon cancer	7.82e-05	0.000886	CcSEcCtD
Sunitinib—Hepatitis—Capecitabine—colon cancer	7.82e-05	0.000886	CcSEcCtD
Sunitinib—MAP4K5—liver—colon cancer	7.82e-05	0.000859	CbGeAlD
Sunitinib—MAP3K3—liver—colon cancer	7.82e-05	0.000859	CbGeAlD
Sunitinib—Nervous system disorder—Fluorouracil—colon cancer	7.8e-05	0.000883	CcSEcCtD
Sunitinib—Thrombocytopenia—Fluorouracil—colon cancer	7.79e-05	0.000882	CcSEcCtD
Sunitinib—Hypoaesthesia—Capecitabine—colon cancer	7.78e-05	0.000882	CcSEcCtD
Sunitinib—Liver function test abnormal—Methotrexate—colon cancer	7.77e-05	0.00088	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Vincristine—colon cancer	7.77e-05	0.00088	CcSEcCtD
Sunitinib—CAMK2G—lymph node—colon cancer	7.74e-05	0.00085	CbGeAlD
Sunitinib—BMP2K—lymph node—colon cancer	7.74e-05	0.00085	CbGeAlD
Sunitinib—Urinary tract disorder—Capecitabine—colon cancer	7.72e-05	0.000875	CcSEcCtD
Sunitinib—CSF1R—bone marrow—colon cancer	7.71e-05	0.000847	CbGeAlD
Sunitinib—Insomnia—Vincristine—colon cancer	7.71e-05	0.000873	CcSEcCtD
Sunitinib—Oedema peripheral—Capecitabine—colon cancer	7.7e-05	0.000873	CcSEcCtD
Sunitinib—KIT—lymphoid tissue—colon cancer	7.69e-05	0.000845	CbGeAlD
Sunitinib—Connective tissue disorder—Capecitabine—colon cancer	7.69e-05	0.000871	CcSEcCtD
Sunitinib—LRRK2—lymph node—colon cancer	7.67e-05	0.000842	CbGeAlD
Sunitinib—Urethral disorder—Capecitabine—colon cancer	7.67e-05	0.000869	CcSEcCtD
Sunitinib—Paraesthesia—Vincristine—colon cancer	7.66e-05	0.000867	CcSEcCtD
Sunitinib—KIT—digestive system—colon cancer	7.6e-05	0.000835	CbGeAlD
Sunitinib—Anorexia—Fluorouracil—colon cancer	7.58e-05	0.000859	CcSEcCtD
Sunitinib—Toxic epidermal necrolysis—Methotrexate—colon cancer	7.58e-05	0.000859	CcSEcCtD
Sunitinib—KDR—vagina—colon cancer	7.57e-05	0.000832	CbGeAlD
Sunitinib—MAP2K5—vagina—colon cancer	7.57e-05	0.000832	CbGeAlD
Sunitinib—PRKAA1—lymph node—colon cancer	7.56e-05	0.00083	CbGeAlD
Sunitinib—FLT1—liver—colon cancer	7.56e-05	0.00083	CbGeAlD
Sunitinib—PDGFRB—lymphoid tissue—colon cancer	7.51e-05	0.000825	CbGeAlD
Sunitinib—Insomnia—Irinotecan—colon cancer	7.51e-05	0.000851	CcSEcCtD
Sunitinib—PTK2B—lymph node—colon cancer	7.47e-05	0.000821	CbGeAlD
Sunitinib—Paraesthesia—Irinotecan—colon cancer	7.46e-05	0.000845	CcSEcCtD
Sunitinib—FLT4—lymph node—colon cancer	7.45e-05	0.000819	CbGeAlD
Sunitinib—PDGFRB—digestive system—colon cancer	7.42e-05	0.000815	CbGeAlD
Sunitinib—Decreased appetite—Vincristine—colon cancer	7.41e-05	0.000839	CcSEcCtD
Sunitinib—Dyspnoea—Irinotecan—colon cancer	7.4e-05	0.000838	CcSEcCtD
Sunitinib—Erythema multiforme—Capecitabine—colon cancer	7.4e-05	0.000838	CcSEcCtD
Sunitinib—CSF1R—vagina—colon cancer	7.39e-05	0.000812	CbGeAlD
Sunitinib—Gastrointestinal disorder—Vincristine—colon cancer	7.36e-05	0.000834	CcSEcCtD
Sunitinib—CSNK1E—lymph node—colon cancer	7.35e-05	0.000808	CbGeAlD
Sunitinib—FGFR1—lymph node—colon cancer	7.35e-05	0.000808	CbGeAlD
Sunitinib—Fatigue—Vincristine—colon cancer	7.35e-05	0.000833	CcSEcCtD
Sunitinib—Eye disorder—Capecitabine—colon cancer	7.31e-05	0.000828	CcSEcCtD
Sunitinib—Dyspepsia—Irinotecan—colon cancer	7.31e-05	0.000828	CcSEcCtD
Sunitinib—Pain—Vincristine—colon cancer	7.29e-05	0.000826	CcSEcCtD
Sunitinib—Constipation—Vincristine—colon cancer	7.29e-05	0.000826	CcSEcCtD
Sunitinib—Flushing—Capecitabine—colon cancer	7.26e-05	0.000822	CcSEcCtD
Sunitinib—Cardiac disorder—Capecitabine—colon cancer	7.26e-05	0.000822	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Fluorouracil—colon cancer	7.24e-05	0.000821	CcSEcCtD
Sunitinib—IRAK4—lymph node—colon cancer	7.24e-05	0.000795	CbGeAlD
Sunitinib—YES1—liver—colon cancer	7.22e-05	0.000793	CbGeAlD
Sunitinib—Decreased appetite—Irinotecan—colon cancer	7.22e-05	0.000818	CcSEcCtD
Sunitinib—ABCC4—renal system—colon cancer	7.21e-05	0.000791	CbGeAlD
Sunitinib—Insomnia—Fluorouracil—colon cancer	7.19e-05	0.000815	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Irinotecan—colon cancer	7.17e-05	0.000812	CcSEcCtD
Sunitinib—Fatigue—Irinotecan—colon cancer	7.16e-05	0.000811	CcSEcCtD
Sunitinib—STK10—liver—colon cancer	7.15e-05	0.000786	CbGeAlD
Sunitinib—Paraesthesia—Fluorouracil—colon cancer	7.14e-05	0.000809	CcSEcCtD
Sunitinib—Pancreatitis—Methotrexate—colon cancer	7.13e-05	0.000808	CcSEcCtD
Sunitinib—TAOK3—liver—colon cancer	7.13e-05	0.000783	CbGeAlD
Sunitinib—Constipation—Irinotecan—colon cancer	7.1e-05	0.000804	CcSEcCtD
Sunitinib—Pain—Irinotecan—colon cancer	7.1e-05	0.000804	CcSEcCtD
Sunitinib—Angiopathy—Capecitabine—colon cancer	7.1e-05	0.000804	CcSEcCtD
Sunitinib—Dyspnoea—Fluorouracil—colon cancer	7.09e-05	0.000803	CcSEcCtD
Sunitinib—PDGFRA—liver—colon cancer	7.08e-05	0.000778	CbGeAlD
Sunitinib—ULK3—lymph node—colon cancer	7.08e-05	0.000777	CbGeAlD
Sunitinib—MAP2K2—lymph node—colon cancer	7.08e-05	0.000777	CbGeAlD
Sunitinib—Immune system disorder—Capecitabine—colon cancer	7.06e-05	0.0008	CcSEcCtD
Sunitinib—Mediastinal disorder—Capecitabine—colon cancer	7.05e-05	0.000798	CcSEcCtD
Sunitinib—MAP3K2—lymph node—colon cancer	7.03e-05	0.000772	CbGeAlD
Sunitinib—Chills—Capecitabine—colon cancer	7.02e-05	0.000795	CcSEcCtD
Sunitinib—KIT—bone marrow—colon cancer	7e-05	0.00077	CbGeAlD
Sunitinib—Dyspepsia—Fluorouracil—colon cancer	7e-05	0.000793	CcSEcCtD
Sunitinib—Arrhythmia—Capecitabine—colon cancer	6.99e-05	0.000791	CcSEcCtD
Sunitinib—ABCC2—renal system—colon cancer	6.97e-05	0.000766	CbGeAlD
Sunitinib—Abdominal discomfort—Methotrexate—colon cancer	6.97e-05	0.00079	CcSEcCtD
Sunitinib—Gastrointestinal pain—Vincristine—colon cancer	6.97e-05	0.00079	CcSEcCtD
Sunitinib—CYP3A7-CYP3A51P—liver—colon cancer	6.97e-05	0.000766	CbGeAlD
Sunitinib—MAP3K7—lymph node—colon cancer	6.96e-05	0.000765	CbGeAlD
Sunitinib—Decreased appetite—Fluorouracil—colon cancer	6.91e-05	0.000783	CcSEcCtD
Sunitinib—Alopecia—Capecitabine—colon cancer	6.91e-05	0.000783	CcSEcCtD
Sunitinib—Pancytopenia—Methotrexate—colon cancer	6.91e-05	0.000783	CcSEcCtD
Sunitinib—TBK1—lymph node—colon cancer	6.88e-05	0.000756	CbGeAlD
Sunitinib—Gastrointestinal disorder—Fluorouracil—colon cancer	6.86e-05	0.000778	CcSEcCtD
Sunitinib—Mental disorder—Capecitabine—colon cancer	6.85e-05	0.000776	CcSEcCtD
Sunitinib—PDGFRB—bone marrow—colon cancer	6.84e-05	0.000752	CbGeAlD
Sunitinib—TYK2—lymph node—colon cancer	6.83e-05	0.000751	CbGeAlD
Sunitinib—Malnutrition—Capecitabine—colon cancer	6.81e-05	0.000771	CcSEcCtD
Sunitinib—Erythema—Capecitabine—colon cancer	6.81e-05	0.000771	CcSEcCtD
Sunitinib—Neutropenia—Methotrexate—colon cancer	6.8e-05	0.000771	CcSEcCtD
Sunitinib—Pain—Fluorouracil—colon cancer	6.8e-05	0.00077	CcSEcCtD
Sunitinib—Gastrointestinal pain—Irinotecan—colon cancer	6.79e-05	0.000769	CcSEcCtD
Sunitinib—Upper respiratory tract infection—Methotrexate—colon cancer	6.76e-05	0.000766	CcSEcCtD
Sunitinib—IRAK1—lymph node—colon cancer	6.75e-05	0.000741	CbGeAlD
Sunitinib—Abdominal pain—Vincristine—colon cancer	6.74e-05	0.000763	CcSEcCtD
Sunitinib—Body temperature increased—Vincristine—colon cancer	6.74e-05	0.000763	CcSEcCtD
Sunitinib—KIT—vagina—colon cancer	6.71e-05	0.000737	CbGeAlD
Sunitinib—Flatulence—Capecitabine—colon cancer	6.71e-05	0.00076	CcSEcCtD
Sunitinib—Dysgeusia—Capecitabine—colon cancer	6.67e-05	0.000755	CcSEcCtD
Sunitinib—RPS6KB1—lymph node—colon cancer	6.62e-05	0.000727	CbGeAlD
Sunitinib—Back pain—Capecitabine—colon cancer	6.59e-05	0.000746	CcSEcCtD
Sunitinib—FGR—lymph node—colon cancer	6.58e-05	0.000723	CbGeAlD
Sunitinib—RET—lymph node—colon cancer	6.58e-05	0.000723	CbGeAlD
Sunitinib—Body temperature increased—Irinotecan—colon cancer	6.56e-05	0.000743	CcSEcCtD
Sunitinib—Abdominal pain—Irinotecan—colon cancer	6.56e-05	0.000743	CcSEcCtD
Sunitinib—PDGFRB—vagina—colon cancer	6.55e-05	0.00072	CbGeAlD
Sunitinib—AXL—lymph node—colon cancer	6.55e-05	0.00072	CbGeAlD
Sunitinib—Muscle spasms—Capecitabine—colon cancer	6.55e-05	0.000742	CcSEcCtD
Sunitinib—Pneumonia—Methotrexate—colon cancer	6.52e-05	0.000739	CcSEcCtD
Sunitinib—Infestation—Methotrexate—colon cancer	6.49e-05	0.000735	CcSEcCtD
Sunitinib—Infestation NOS—Methotrexate—colon cancer	6.49e-05	0.000735	CcSEcCtD
Sunitinib—Depression—Methotrexate—colon cancer	6.47e-05	0.000733	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Methotrexate—colon cancer	6.43e-05	0.000728	CcSEcCtD
Sunitinib—KDR—liver—colon cancer	6.39e-05	0.000702	CbGeAlD
Sunitinib—MAP2K5—liver—colon cancer	6.39e-05	0.000702	CbGeAlD
Sunitinib—Renal failure—Methotrexate—colon cancer	6.38e-05	0.000722	CcSEcCtD
Sunitinib—Stomatitis—Methotrexate—colon cancer	6.32e-05	0.000716	CcSEcCtD
Sunitinib—SLK—lymph node—colon cancer	6.31e-05	0.000693	CbGeAlD
Sunitinib—Anaemia—Capecitabine—colon cancer	6.29e-05	0.000713	CcSEcCtD
Sunitinib—Body temperature increased—Fluorouracil—colon cancer	6.29e-05	0.000712	CcSEcCtD
Sunitinib—Hypersensitivity—Vincristine—colon cancer	6.28e-05	0.000712	CcSEcCtD
Sunitinib—CSF1R—liver—colon cancer	6.23e-05	0.000685	CbGeAlD
Sunitinib—JAK2—lymph node—colon cancer	6.22e-05	0.000683	CbGeAlD
Sunitinib—Hepatobiliary disease—Methotrexate—colon cancer	6.13e-05	0.000695	CcSEcCtD
Sunitinib—FYN—lymph node—colon cancer	6.13e-05	0.000674	CbGeAlD
Sunitinib—Epistaxis—Methotrexate—colon cancer	6.12e-05	0.000693	CcSEcCtD
Sunitinib—Hypersensitivity—Irinotecan—colon cancer	6.12e-05	0.000693	CcSEcCtD
Sunitinib—Asthenia—Vincristine—colon cancer	6.12e-05	0.000693	CcSEcCtD
Sunitinib—Leukopenia—Capecitabine—colon cancer	6.09e-05	0.00069	CcSEcCtD
Sunitinib—MAP4K5—lymph node—colon cancer	5.99e-05	0.000658	CbGeAlD
Sunitinib—MAP3K3—lymph node—colon cancer	5.99e-05	0.000658	CbGeAlD
Sunitinib—Asthenia—Irinotecan—colon cancer	5.96e-05	0.000675	CcSEcCtD
Sunitinib—Cough—Capecitabine—colon cancer	5.94e-05	0.000673	CcSEcCtD
Sunitinib—ABCC4—digestive system—colon cancer	5.91e-05	0.000649	CbGeAlD
Sunitinib—Hypertension—Capecitabine—colon cancer	5.88e-05	0.000666	CcSEcCtD
Sunitinib—Hypersensitivity—Fluorouracil—colon cancer	5.86e-05	0.000664	CcSEcCtD
Sunitinib—Haemoglobin—Methotrexate—colon cancer	5.85e-05	0.000663	CcSEcCtD
Sunitinib—Diarrhoea—Vincristine—colon cancer	5.83e-05	0.000661	CcSEcCtD
Sunitinib—Hepatitis—Methotrexate—colon cancer	5.82e-05	0.00066	CcSEcCtD
Sunitinib—Haemorrhage—Methotrexate—colon cancer	5.82e-05	0.00066	CcSEcCtD
Sunitinib—Chest pain—Capecitabine—colon cancer	5.8e-05	0.000657	CcSEcCtD
Sunitinib—Myalgia—Capecitabine—colon cancer	5.8e-05	0.000657	CcSEcCtD
Sunitinib—Arthralgia—Capecitabine—colon cancer	5.8e-05	0.000657	CcSEcCtD
Sunitinib—FLT1—lymph node—colon cancer	5.79e-05	0.000636	CbGeAlD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	5.76e-05	0.000652	CcSEcCtD
Sunitinib—Urinary tract disorder—Methotrexate—colon cancer	5.75e-05	0.000651	CcSEcCtD
Sunitinib—EPHB6—lymph node—colon cancer	5.73e-05	0.000629	CbGeAlD
Sunitinib—ABCC2—digestive system—colon cancer	5.72e-05	0.000628	CbGeAlD
Sunitinib—KCNH2—renal system—colon cancer	5.72e-05	0.000628	CbGeAlD
Sunitinib—Urethral disorder—Methotrexate—colon cancer	5.71e-05	0.000647	CcSEcCtD
Sunitinib—Diarrhoea—Irinotecan—colon cancer	5.68e-05	0.000643	CcSEcCtD
Sunitinib—Dry mouth—Capecitabine—colon cancer	5.67e-05	0.000642	CcSEcCtD
Sunitinib—KIT—liver—colon cancer	5.66e-05	0.000622	CbGeAlD
Sunitinib—Dizziness—Vincristine—colon cancer	5.64e-05	0.000639	CcSEcCtD
Sunitinib—Pruritus—Fluorouracil—colon cancer	5.63e-05	0.000637	CcSEcCtD
Sunitinib—Oedema—Capecitabine—colon cancer	5.56e-05	0.000629	CcSEcCtD
Sunitinib—ABCB1—blood vessel—colon cancer	5.55e-05	0.00061	CbGeAlD
Sunitinib—YES1—lymph node—colon cancer	5.53e-05	0.000608	CbGeAlD
Sunitinib—PDGFRB—liver—colon cancer	5.53e-05	0.000607	CbGeAlD
Sunitinib—Infection—Capecitabine—colon cancer	5.52e-05	0.000625	CcSEcCtD
Sunitinib—Erythema multiforme—Methotrexate—colon cancer	5.51e-05	0.000624	CcSEcCtD
Sunitinib—Dizziness—Irinotecan—colon cancer	5.49e-05	0.000622	CcSEcCtD
Sunitinib—STK10—lymph node—colon cancer	5.48e-05	0.000603	CbGeAlD
Sunitinib—Shock—Capecitabine—colon cancer	5.47e-05	0.000619	CcSEcCtD
Sunitinib—TAOK3—lymph node—colon cancer	5.46e-05	0.0006	CbGeAlD
Sunitinib—Nervous system disorder—Capecitabine—colon cancer	5.45e-05	0.000617	CcSEcCtD
Sunitinib—ABCC4—bone marrow—colon cancer	5.45e-05	0.000598	CbGeAlD
Sunitinib—Eye disorder—Methotrexate—colon cancer	5.44e-05	0.000616	CcSEcCtD
Sunitinib—Diarrhoea—Fluorouracil—colon cancer	5.44e-05	0.000616	CcSEcCtD
Sunitinib—Thrombocytopenia—Capecitabine—colon cancer	5.44e-05	0.000616	CcSEcCtD
Sunitinib—PDGFRA—lymph node—colon cancer	5.43e-05	0.000596	CbGeAlD
Sunitinib—Vomiting—Vincristine—colon cancer	5.42e-05	0.000614	CcSEcCtD
Sunitinib—Cardiac disorder—Methotrexate—colon cancer	5.4e-05	0.000612	CcSEcCtD
Sunitinib—Skin disorder—Capecitabine—colon cancer	5.4e-05	0.000611	CcSEcCtD
Sunitinib—Rash—Vincristine—colon cancer	5.38e-05	0.000609	CcSEcCtD
Sunitinib—Dermatitis—Vincristine—colon cancer	5.37e-05	0.000608	CcSEcCtD
Sunitinib—Headache—Vincristine—colon cancer	5.34e-05	0.000605	CcSEcCtD
Sunitinib—Anorexia—Capecitabine—colon cancer	5.3e-05	0.0006	CcSEcCtD
Sunitinib—Angiopathy—Methotrexate—colon cancer	5.28e-05	0.000598	CcSEcCtD
Sunitinib—Vomiting—Irinotecan—colon cancer	5.28e-05	0.000598	CcSEcCtD
Sunitinib—Immune system disorder—Methotrexate—colon cancer	5.26e-05	0.000596	CcSEcCtD
Sunitinib—Dizziness—Fluorouracil—colon cancer	5.26e-05	0.000596	CcSEcCtD
Sunitinib—Mediastinal disorder—Methotrexate—colon cancer	5.25e-05	0.000594	CcSEcCtD
Sunitinib—Rash—Irinotecan—colon cancer	5.23e-05	0.000593	CcSEcCtD
Sunitinib—Dermatitis—Irinotecan—colon cancer	5.23e-05	0.000592	CcSEcCtD
Sunitinib—Chills—Methotrexate—colon cancer	5.22e-05	0.000592	CcSEcCtD
Sunitinib—Headache—Irinotecan—colon cancer	5.2e-05	0.000589	CcSEcCtD
Sunitinib—Alopecia—Methotrexate—colon cancer	5.14e-05	0.000583	CcSEcCtD
Sunitinib—Mental disorder—Methotrexate—colon cancer	5.1e-05	0.000578	CcSEcCtD
Sunitinib—Erythema—Methotrexate—colon cancer	5.07e-05	0.000574	CcSEcCtD
Sunitinib—Malnutrition—Methotrexate—colon cancer	5.07e-05	0.000574	CcSEcCtD
Sunitinib—Nausea—Vincristine—colon cancer	5.06e-05	0.000574	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Capecitabine—colon cancer	5.06e-05	0.000573	CcSEcCtD
Sunitinib—Vomiting—Fluorouracil—colon cancer	5.06e-05	0.000573	CcSEcCtD
Sunitinib—Insomnia—Capecitabine—colon cancer	5.03e-05	0.000569	CcSEcCtD
Sunitinib—Rash—Fluorouracil—colon cancer	5.01e-05	0.000568	CcSEcCtD
Sunitinib—Dermatitis—Fluorouracil—colon cancer	5.01e-05	0.000567	CcSEcCtD
Sunitinib—Paraesthesia—Capecitabine—colon cancer	4.99e-05	0.000565	CcSEcCtD
Sunitinib—Headache—Fluorouracil—colon cancer	4.98e-05	0.000564	CcSEcCtD
Sunitinib—Dysgeusia—Methotrexate—colon cancer	4.96e-05	0.000562	CcSEcCtD
Sunitinib—Dyspnoea—Capecitabine—colon cancer	4.95e-05	0.000561	CcSEcCtD
Sunitinib—Nausea—Irinotecan—colon cancer	4.93e-05	0.000559	CcSEcCtD
Sunitinib—Back pain—Methotrexate—colon cancer	4.9e-05	0.000555	CcSEcCtD
Sunitinib—KDR—lymph node—colon cancer	4.9e-05	0.000538	CbGeAlD
Sunitinib—MAP2K5—lymph node—colon cancer	4.9e-05	0.000538	CbGeAlD
Sunitinib—Dyspepsia—Capecitabine—colon cancer	4.89e-05	0.000554	CcSEcCtD
Sunitinib—Decreased appetite—Capecitabine—colon cancer	4.83e-05	0.000547	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Capecitabine—colon cancer	4.8e-05	0.000543	CcSEcCtD
Sunitinib—Fatigue—Capecitabine—colon cancer	4.79e-05	0.000543	CcSEcCtD
Sunitinib—CSF1R—lymph node—colon cancer	4.78e-05	0.000525	CbGeAlD
Sunitinib—Constipation—Capecitabine—colon cancer	4.75e-05	0.000538	CcSEcCtD
Sunitinib—Pain—Capecitabine—colon cancer	4.75e-05	0.000538	CcSEcCtD
Sunitinib—Nausea—Fluorouracil—colon cancer	4.72e-05	0.000535	CcSEcCtD
Sunitinib—CYP3A5—renal system—colon cancer	4.72e-05	0.000519	CbGeAlD
Sunitinib—Anaemia—Methotrexate—colon cancer	4.68e-05	0.000531	CcSEcCtD
Sunitinib—Gastrointestinal pain—Capecitabine—colon cancer	4.54e-05	0.000515	CcSEcCtD
Sunitinib—Leukopenia—Methotrexate—colon cancer	4.54e-05	0.000514	CcSEcCtD
Sunitinib—Cough—Methotrexate—colon cancer	4.42e-05	0.000501	CcSEcCtD
Sunitinib—ABCC4—liver—colon cancer	4.4e-05	0.000484	CbGeAlD
Sunitinib—Body temperature increased—Capecitabine—colon cancer	4.39e-05	0.000498	CcSEcCtD
Sunitinib—Abdominal pain—Capecitabine—colon cancer	4.39e-05	0.000498	CcSEcCtD
Sunitinib—Convulsion—Methotrexate—colon cancer	4.39e-05	0.000497	CcSEcCtD
Sunitinib—KIT—lymph node—colon cancer	4.34e-05	0.000477	CbGeAlD
Sunitinib—KCNH2—bone marrow—colon cancer	4.32e-05	0.000475	CbGeAlD
Sunitinib—Chest pain—Methotrexate—colon cancer	4.32e-05	0.000489	CcSEcCtD
Sunitinib—Myalgia—Methotrexate—colon cancer	4.32e-05	0.000489	CcSEcCtD
Sunitinib—Arthralgia—Methotrexate—colon cancer	4.32e-05	0.000489	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	4.29e-05	0.000485	CcSEcCtD
Sunitinib—ABCC2—liver—colon cancer	4.26e-05	0.000468	CbGeAlD
Sunitinib—PDGFRB—lymph node—colon cancer	4.24e-05	0.000466	CbGeAlD
Sunitinib—KCNH2—vagina—colon cancer	4.14e-05	0.000455	CbGeAlD
Sunitinib—Infection—Methotrexate—colon cancer	4.11e-05	0.000466	CcSEcCtD
Sunitinib—Hypersensitivity—Capecitabine—colon cancer	4.09e-05	0.000464	CcSEcCtD
Sunitinib—Nervous system disorder—Methotrexate—colon cancer	4.06e-05	0.00046	CcSEcCtD
Sunitinib—Thrombocytopenia—Methotrexate—colon cancer	4.05e-05	0.000459	CcSEcCtD
Sunitinib—Skin disorder—Methotrexate—colon cancer	4.02e-05	0.000455	CcSEcCtD
Sunitinib—Asthenia—Capecitabine—colon cancer	3.99e-05	0.000452	CcSEcCtD
Sunitinib—Anorexia—Methotrexate—colon cancer	3.94e-05	0.000447	CcSEcCtD
Sunitinib—Pruritus—Capecitabine—colon cancer	3.93e-05	0.000445	CcSEcCtD
Sunitinib—CYP3A5—digestive system—colon cancer	3.87e-05	0.000425	CbGeAlD
Sunitinib—ABCG2—bone marrow—colon cancer	3.85e-05	0.000422	CbGeAlD
Sunitinib—Diarrhoea—Capecitabine—colon cancer	3.8e-05	0.000431	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Methotrexate—colon cancer	3.77e-05	0.000427	CcSEcCtD
Sunitinib—Insomnia—Methotrexate—colon cancer	3.74e-05	0.000424	CcSEcCtD
Sunitinib—Paraesthesia—Methotrexate—colon cancer	3.71e-05	0.000421	CcSEcCtD
Sunitinib—Dyspnoea—Methotrexate—colon cancer	3.69e-05	0.000418	CcSEcCtD
Sunitinib—ABCG2—vagina—colon cancer	3.68e-05	0.000405	CbGeAlD
Sunitinib—Dizziness—Capecitabine—colon cancer	3.67e-05	0.000416	CcSEcCtD
Sunitinib—Dyspepsia—Methotrexate—colon cancer	3.64e-05	0.000412	CcSEcCtD
Sunitinib—Decreased appetite—Methotrexate—colon cancer	3.6e-05	0.000407	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Methotrexate—colon cancer	3.57e-05	0.000405	CcSEcCtD
Sunitinib—Fatigue—Methotrexate—colon cancer	3.57e-05	0.000404	CcSEcCtD
Sunitinib—CYP3A4—renal system—colon cancer	3.54e-05	0.000389	CbGeAlD
Sunitinib—Pain—Methotrexate—colon cancer	3.54e-05	0.000401	CcSEcCtD
Sunitinib—Vomiting—Capecitabine—colon cancer	3.53e-05	0.0004	CcSEcCtD
Sunitinib—Rash—Capecitabine—colon cancer	3.5e-05	0.000397	CcSEcCtD
Sunitinib—Dermatitis—Capecitabine—colon cancer	3.5e-05	0.000397	CcSEcCtD
Sunitinib—Headache—Capecitabine—colon cancer	3.48e-05	0.000394	CcSEcCtD
Sunitinib—CYP3A5—vagina—colon cancer	3.42e-05	0.000376	CbGeAlD
Sunitinib—Gastrointestinal pain—Methotrexate—colon cancer	3.38e-05	0.000383	CcSEcCtD
Sunitinib—ABCC4—lymph node—colon cancer	3.38e-05	0.000371	CbGeAlD
Sunitinib—ABCB1—embryo—colon cancer	3.31e-05	0.000364	CbGeAlD
Sunitinib—Nausea—Capecitabine—colon cancer	3.3e-05	0.000374	CcSEcCtD
Sunitinib—Body temperature increased—Methotrexate—colon cancer	3.27e-05	0.00037	CcSEcCtD
Sunitinib—Abdominal pain—Methotrexate—colon cancer	3.27e-05	0.00037	CcSEcCtD
Sunitinib—ABCC2—lymph node—colon cancer	3.27e-05	0.000359	CbGeAlD
Sunitinib—ABCG2—liver—colon cancer	3.11e-05	0.000341	CbGeAlD
Sunitinib—Hypersensitivity—Methotrexate—colon cancer	3.05e-05	0.000345	CcSEcCtD
Sunitinib—Asthenia—Methotrexate—colon cancer	2.97e-05	0.000336	CcSEcCtD
Sunitinib—Pruritus—Methotrexate—colon cancer	2.93e-05	0.000332	CcSEcCtD
Sunitinib—CYP3A4—digestive system—colon cancer	2.91e-05	0.000319	CbGeAlD
Sunitinib—CYP3A5—liver—colon cancer	2.88e-05	0.000317	CbGeAlD
Sunitinib—Diarrhoea—Methotrexate—colon cancer	2.83e-05	0.000321	CcSEcCtD
Sunitinib—Dizziness—Methotrexate—colon cancer	2.74e-05	0.00031	CcSEcCtD
Sunitinib—ABCB1—epithelium—colon cancer	2.7e-05	0.000297	CbGeAlD
Sunitinib—KCNH2—lymph node—colon cancer	2.68e-05	0.000294	CbGeAlD
Sunitinib—Vomiting—Methotrexate—colon cancer	2.63e-05	0.000298	CcSEcCtD
Sunitinib—Rash—Methotrexate—colon cancer	2.61e-05	0.000295	CcSEcCtD
Sunitinib—Dermatitis—Methotrexate—colon cancer	2.61e-05	0.000295	CcSEcCtD
Sunitinib—Headache—Methotrexate—colon cancer	2.59e-05	0.000294	CcSEcCtD
Sunitinib—ABCB1—renal system—colon cancer	2.51e-05	0.000276	CbGeAlD
Sunitinib—Nausea—Methotrexate—colon cancer	2.46e-05	0.000278	CcSEcCtD
Sunitinib—ABCG2—lymph node—colon cancer	2.38e-05	0.000262	CbGeAlD
Sunitinib—CYP3A4—liver—colon cancer	2.16e-05	0.000238	CbGeAlD
Sunitinib—ABCB1—lymphoid tissue—colon cancer	2.08e-05	0.000229	CbGeAlD
Sunitinib—ABCB1—digestive system—colon cancer	2.06e-05	0.000226	CbGeAlD
Sunitinib—ABCB1—bone marrow—colon cancer	1.9e-05	0.000208	CbGeAlD
Sunitinib—ABCB1—vagina—colon cancer	1.82e-05	0.0002	CbGeAlD
Sunitinib—ABCB1—liver—colon cancer	1.53e-05	0.000168	CbGeAlD
Sunitinib—ABCB1—lymph node—colon cancer	1.17e-05	0.000129	CbGeAlD
Sunitinib—TYK2—Signaling Pathways—NRAS—colon cancer	7.97e-07	6.25e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—VEGFA—colon cancer	7.97e-07	6.25e-06	CbGpPWpGaD
Sunitinib—TYK2—Immune System—AKT1—colon cancer	7.97e-07	6.25e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—EGFR—colon cancer	7.89e-07	6.19e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—PIK3CA—colon cancer	7.89e-07	6.18e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PTGS2—colon cancer	7.88e-07	6.18e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—NRAS—colon cancer	7.87e-07	6.17e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CASP3—colon cancer	7.87e-07	6.17e-06	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—AKT1—colon cancer	7.87e-07	6.17e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—EGFR—colon cancer	7.86e-07	6.16e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CCND1—colon cancer	7.85e-07	6.15e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—AKT1—colon cancer	7.85e-07	6.15e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—EP300—colon cancer	7.85e-07	6.15e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—HRAS—colon cancer	7.83e-07	6.14e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—VEGFA—colon cancer	7.83e-07	6.14e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—VEGFA—colon cancer	7.83e-07	6.14e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—TP53—colon cancer	7.83e-07	6.14e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—TP53—colon cancer	7.83e-07	6.14e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—EP300—colon cancer	7.83e-07	6.13e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—KRAS—colon cancer	7.81e-07	6.13e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PTGS2—colon cancer	7.81e-07	6.12e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—AKT1—colon cancer	7.78e-07	6.1e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—PIK3CA—colon cancer	7.77e-07	6.1e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CTNNB1—colon cancer	7.77e-07	6.09e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—HRAS—colon cancer	7.77e-07	6.09e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—KRAS—colon cancer	7.77e-07	6.09e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—NRAS—colon cancer	7.73e-07	6.06e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—NRAS—colon cancer	7.73e-07	6.06e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—PIK3CA—colon cancer	7.73e-07	6.06e-06	CbGpPWpGaD
Sunitinib—KIT—Immune System—AKT1—colon cancer	7.73e-07	6.06e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—AKT1—colon cancer	7.73e-07	6.06e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—HRAS—colon cancer	7.72e-07	6.05e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—HRAS—colon cancer	7.67e-07	6.01e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CCND1—colon cancer	7.66e-07	6e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—MYC—colon cancer	7.65e-07	6e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—HRAS—colon cancer	7.65e-07	6e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—HRAS—colon cancer	7.65e-07	6e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—TYMS—colon cancer	7.65e-07	5.99e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TGFB1—colon cancer	7.63e-07	5.98e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—PIK3CA—colon cancer	7.63e-07	5.98e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—TP53—colon cancer	7.63e-07	5.98e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—SRC—colon cancer	7.63e-07	5.98e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—SRC—colon cancer	7.61e-07	5.97e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CDKN1A—colon cancer	7.59e-07	5.95e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CTNNB1—colon cancer	7.58e-07	5.95e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CASP3—colon cancer	7.58e-07	5.95e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CASP3—colon cancer	7.54e-07	5.91e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—HRAS—colon cancer	7.49e-07	5.87e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—HRAS—colon cancer	7.49e-07	5.87e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—HRAS—colon cancer	7.48e-07	5.87e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—EGFR—colon cancer	7.48e-07	5.87e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—HRAS—colon cancer	7.46e-07	5.85e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—KRAS—colon cancer	7.45e-07	5.84e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—PIK3CA—colon cancer	7.45e-07	5.84e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—VEGFA—colon cancer	7.43e-07	5.83e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—MYC—colon cancer	7.43e-07	5.82e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—KRAS—colon cancer	7.43e-07	5.82e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—VEGFA—colon cancer	7.41e-07	5.81e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CDKN1A—colon cancer	7.41e-07	5.81e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TGFB1—colon cancer	7.41e-07	5.81e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—PIK3CA—colon cancer	7.39e-07	5.79e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—AKT1—colon cancer	7.39e-07	5.79e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CCND1—colon cancer	7.38e-07	5.79e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—AKT1—colon cancer	7.35e-07	5.77e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CCND1—colon cancer	7.34e-07	5.76e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—NRAS—colon cancer	7.34e-07	5.75e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MYC—colon cancer	7.33e-07	5.75e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—AKT1—colon cancer	7.33e-07	5.75e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—NRAS—colon cancer	7.32e-07	5.74e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TGFB1—colon cancer	7.32e-07	5.74e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—AKT1—colon cancer	7.31e-07	5.73e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CTNNB1—colon cancer	7.31e-07	5.73e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—HRAS—colon cancer	7.3e-07	5.72e-06	CbGpPWpGaD
Sunitinib—JAK2—GPCR downstream signaling—AKT1—colon cancer	7.28e-07	5.7e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CTNNB1—colon cancer	7.27e-07	5.7e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—EGFR—colon cancer	7.26e-07	5.7e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—AKT1—colon cancer	7.26e-07	5.69e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—EP300—colon cancer	7.22e-07	5.66e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CASP3—colon cancer	7.21e-07	5.65e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MYC—colon cancer	7.2e-07	5.65e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MYC—colon cancer	7.2e-07	5.65e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—HRAS—colon cancer	7.19e-07	5.64e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TGFB1—colon cancer	7.19e-07	5.63e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TGFB1—colon cancer	7.19e-07	5.63e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—PIK3CA—colon cancer	7.18e-07	5.63e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PPARG—colon cancer	7.18e-07	5.63e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—EGFR—colon cancer	7.17e-07	5.62e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—HRAS—colon cancer	7.15e-07	5.61e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CDKN1A—colon cancer	7.14e-07	5.6e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—PIK3CA—colon cancer	7.14e-07	5.6e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—AKT1—colon cancer	7.13e-07	5.59e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—AKT1—colon cancer	7.12e-07	5.59e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CDKN1A—colon cancer	7.1e-07	5.57e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—KRAS—colon cancer	7.07e-07	5.54e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—HRAS—colon cancer	7.06e-07	5.54e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—EP300—colon cancer	7.05e-07	5.53e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—EGFR—colon cancer	7.05e-07	5.52e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—EGFR—colon cancer	7.05e-07	5.52e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—SRC—colon cancer	7.02e-07	5.51e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CCND1—colon cancer	7.02e-07	5.5e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CTNNB1—colon cancer	6.95e-07	5.45e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—AKT1—colon cancer	6.91e-07	5.42e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—HRAS—colon cancer	6.89e-07	5.4e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—KRAS—colon cancer	6.86e-07	5.38e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—AKT1—colon cancer	6.86e-07	5.38e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—SRC—colon cancer	6.86e-07	5.37e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—PIK3CA—colon cancer	6.85e-07	5.37e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—VEGFA—colon cancer	6.84e-07	5.36e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—HRAS—colon cancer	6.84e-07	5.36e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MYC—colon cancer	6.84e-07	5.36e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—PIK3CA—colon cancer	6.82e-07	5.35e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TGFB1—colon cancer	6.82e-07	5.35e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MYC—colon cancer	6.82e-07	5.35e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—AKT1—colon cancer	6.82e-07	5.35e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TGFB1—colon cancer	6.8e-07	5.33e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—EP300—colon cancer	6.8e-07	5.33e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CDKN1A—colon cancer	6.79e-07	5.32e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—KRAS—colon cancer	6.78e-07	5.31e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—AKT1—colon cancer	6.77e-07	5.31e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—EP300—colon cancer	6.76e-07	5.3e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—NRAS—colon cancer	6.76e-07	5.3e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—AKT1—colon cancer	6.75e-07	5.29e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—AKT1—colon cancer	6.75e-07	5.29e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—EGFR—colon cancer	6.69e-07	5.24e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—VEGFA—colon cancer	6.68e-07	5.23e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—EGFR—colon cancer	6.67e-07	5.23e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—KRAS—colon cancer	6.66e-07	5.22e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—KRAS—colon cancer	6.66e-07	5.22e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—HRAS—colon cancer	6.64e-07	5.21e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—TP53—colon cancer	6.62e-07	5.19e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—AKT1—colon cancer	6.61e-07	5.18e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—AKT1—colon cancer	6.61e-07	5.18e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—SRC—colon cancer	6.61e-07	5.18e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—AKT1—colon cancer	6.61e-07	5.18e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—HRAS—colon cancer	6.61e-07	5.18e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—NRAS—colon cancer	6.6e-07	5.17e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—AKT1—colon cancer	6.59e-07	5.17e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—SRC—colon cancer	6.57e-07	5.15e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—EP300—colon cancer	6.55e-07	5.14e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—EP300—colon cancer	6.5e-07	5.09e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—PIK3CA—colon cancer	6.49e-07	5.09e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—EP300—colon cancer	6.46e-07	5.06e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—AKT1—colon cancer	6.44e-07	5.05e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—VEGFA—colon cancer	6.44e-07	5.05e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—VEGFA—colon cancer	6.4e-07	5.02e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—NRAS—colon cancer	6.36e-07	4.98e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—AKT1—colon cancer	6.35e-07	4.98e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—HRAS—colon cancer	6.34e-07	4.97e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—NRAS—colon cancer	6.32e-07	4.96e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—AKT1—colon cancer	6.32e-07	4.95e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—KRAS—colon cancer	6.32e-07	4.95e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—HRAS—colon cancer	6.31e-07	4.95e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—PIK3CA—colon cancer	6.3e-07	4.94e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—KRAS—colon cancer	6.3e-07	4.94e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MYC—colon cancer	6.3e-07	4.94e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TP53—colon cancer	6.28e-07	4.93e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—SRC—colon cancer	6.28e-07	4.92e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TGFB1—colon cancer	6.28e-07	4.92e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—AKT1—colon cancer	6.23e-07	4.89e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—PIK3CA—colon cancer	6.23e-07	4.88e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—EGFR—colon cancer	6.16e-07	4.83e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MYC—colon cancer	6.14e-07	4.82e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TGFB1—colon cancer	6.13e-07	4.8e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—VEGFA—colon cancer	6.12e-07	4.8e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—PIK3CA—colon cancer	6.12e-07	4.79e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—PIK3CA—colon cancer	6.12e-07	4.79e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TP53—colon cancer	6.1e-07	4.78e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—AKT1—colon cancer	6.08e-07	4.77e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—NRAS—colon cancer	6.04e-07	4.74e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—AKT1—colon cancer	6.04e-07	4.73e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TP53—colon cancer	6.02e-07	4.72e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—EGFR—colon cancer	6.01e-07	4.71e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—HRAS—colon cancer	6.01e-07	4.71e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MYC—colon cancer	5.92e-07	4.64e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TP53—colon cancer	5.92e-07	4.64e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TP53—colon cancer	5.92e-07	4.64e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TGFB1—colon cancer	5.91e-07	4.63e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MYC—colon cancer	5.89e-07	4.62e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TGFB1—colon cancer	5.88e-07	4.61e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—AKT1—colon cancer	5.86e-07	4.6e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—HRAS—colon cancer	5.83e-07	4.57e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—AKT1—colon cancer	5.83e-07	4.57e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—KRAS—colon cancer	5.82e-07	4.56e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—PIK3CA—colon cancer	5.8e-07	4.55e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—EGFR—colon cancer	5.79e-07	4.54e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—PIK3CA—colon cancer	5.79e-07	4.54e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—EGFR—colon cancer	5.76e-07	4.52e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—HRAS—colon cancer	5.76e-07	4.52e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—KRAS—colon cancer	5.68e-07	4.45e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—HRAS—colon cancer	5.66e-07	4.44e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—HRAS—colon cancer	5.66e-07	4.44e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PTGS2—colon cancer	5.65e-07	4.43e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MYC—colon cancer	5.63e-07	4.41e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TGFB1—colon cancer	5.61e-07	4.4e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TP53—colon cancer	5.61e-07	4.4e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TP53—colon cancer	5.6e-07	4.39e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—AKT1—colon cancer	5.59e-07	4.39e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—AKT1—colon cancer	5.57e-07	4.37e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—EGFR—colon cancer	5.51e-07	4.32e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—KRAS—colon cancer	5.47e-07	4.29e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—KRAS—colon cancer	5.44e-07	4.27e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PPARG—colon cancer	5.42e-07	4.25e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—HRAS—colon cancer	5.37e-07	4.21e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—HRAS—colon cancer	5.36e-07	4.2e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—PIK3CA—colon cancer	5.34e-07	4.19e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—AKT1—colon cancer	5.31e-07	4.16e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—PIK3CA—colon cancer	5.21e-07	4.09e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—KRAS—colon cancer	5.2e-07	4.08e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TP53—colon cancer	5.17e-07	4.05e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—AKT1—colon cancer	5.15e-07	4.04e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—AKT1—colon cancer	5.09e-07	3.99e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TP53—colon cancer	5.04e-07	3.96e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—PIK3CA—colon cancer	5.03e-07	3.94e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—PIK3CA—colon cancer	5e-07	3.92e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—AKT1—colon cancer	5e-07	3.92e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—AKT1—colon cancer	5e-07	3.92e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—HRAS—colon cancer	4.94e-07	3.88e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TP53—colon cancer	4.86e-07	3.81e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PIK3CA—colon cancer	4.85e-07	3.8e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TP53—colon cancer	4.84e-07	3.79e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—HRAS—colon cancer	4.82e-07	3.78e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PIK3CA—colon cancer	4.81e-07	3.77e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ABCB1—colon cancer	4.8e-07	3.76e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—PIK3CA—colon cancer	4.78e-07	3.75e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—AKT1—colon cancer	4.74e-07	3.72e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—AKT1—colon cancer	4.73e-07	3.71e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—TYMS—colon cancer	4.71e-07	3.69e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—EP300—colon cancer	4.7e-07	3.68e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—HRAS—colon cancer	4.65e-07	3.65e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—HRAS—colon cancer	4.63e-07	3.63e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TP53—colon cancer	4.62e-07	3.62e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—HRAS—colon cancer	4.42e-07	3.47e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—AKT1—colon cancer	4.37e-07	3.42e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PTGS2—colon cancer	4.26e-07	3.34e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—AKT1—colon cancer	4.26e-07	3.34e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—AKT1—colon cancer	4.11e-07	3.22e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—AKT1—colon cancer	4.08e-07	3.2e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—AKT1—colon cancer	3.96e-07	3.11e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—AKT1—colon cancer	3.93e-07	3.08e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—AKT1—colon cancer	3.9e-07	3.06e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—EP300—colon cancer	3.54e-07	2.78e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CA—colon cancer	3.47e-07	2.72e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PPARG—colon cancer	3.34e-07	2.62e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—AKT1—colon cancer	2.84e-07	2.22e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PTGS2—colon cancer	2.63e-07	2.06e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CA—colon cancer	2.62e-07	2.06e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—EP300—colon cancer	2.18e-07	1.71e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—AKT1—colon cancer	2.14e-07	1.68e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CA—colon cancer	1.62e-07	1.27e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—AKT1—colon cancer	1.32e-07	1.03e-06	CbGpPWpGaD
